Sun Pharma Q1 Review – U.S. Specialty Continues To Grow; Strong Traction In India Business: Centrum Broking

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Sun Pharmaceutical Industries Ltd. reported record Q1 FY22 earnings well ahead of our estimates adjusting for exceptional charges.

Global specialty has continuously outperformed amid pandemic and delivered significant growth despite the generic entry in Absorica.

Sun Pharma’s management expects to sustain strong double digit growth for Ilumya and Cequa in FY22E.

Taro business recovered and was stable sequentially and excluding-Taro, U.S. segment reported strong growth driven by specialty portfolio.

India business reported strong traction even excluding Covid-19 drugs basket.

This revenue traction has driven strong support to Ebitda margins at 29% reflect higher research and development spend and varied expenses amid pandemic.

We look forward to incremental growth in the specialty basket which would drive higher margins.

Click on the attachment to read the full report:

Centrum Sun Pharma – Q1FY22 Results Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Most Related Links :
dutifulnews Governmental News Finance News

Source link

Back to top button